Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Jiangsu Simcere Pharmaceutical Company, Ltd., commonly referred to as Simcere, is a prominent player in the pharmaceutical industry, headquartered in Nanjing, China. Founded in 1995, the company has established itself as a leader in the development, manufacturing, and marketing of innovative medicines, particularly in oncology, central nervous system disorders, and autoimmune diseases.
With a strong presence in both domestic and international markets, Simcere has achieved significant milestones, including numerous product approvals and partnerships that enhance its research capabilities. The company’s core offerings include a range of proprietary drugs and generic formulations, distinguished by their quality and efficacy. Simcere's commitment to research and development positions it favourably in the competitive landscape, making it a notable contributor to advancements in healthcare.
-14 vs industry average
Jiangsu Simcere Pharmaceutical Company, Ltd.’s score of 28 is lower than 46% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the most carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
No reported emissions data is available for Jiangsu Simcere Pharmaceutical Company, Ltd. yet.
Jiangsu Simcere Pharmaceutical Company, Ltd., headquartered in China (CN), currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Simcere Pharmaceutical Group Limited, which may influence its climate-related initiatives and reporting.
Despite the lack of direct emissions data, Jiangsu Simcere is part of a corporate family that may have broader climate commitments. However, there are no documented reduction targets or climate pledges available for Jiangsu Simcere at this time. The absence of specific initiatives or targets suggests that the company may still be in the early stages of developing its climate strategy.
As a pharmaceutical company, Jiangsu Simcere operates within an industry increasingly focused on sustainability and carbon reduction. The lack of emissions data and reduction commitments highlights an opportunity for the company to enhance its environmental accountability and align with industry standards for climate action.
No climate goals have been disclosed for Jiangsu Simcere Pharmaceutical Company, Ltd. yet.
No scope 3 category breakdown has been disclosed yet.


No peer comparison is available for Jiangsu Simcere Pharmaceutical Company, Ltd. yet.
PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more